Risperidone in the treatment of bipolar mania

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 2, 2006, Pages 127-138

  Sajatovic, Martha ^a,d   Madhusoodanan, Subramoniam ^b   Fuller, Matthew A ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antipsychotic; Bipolar disorder; Mania; Psychopharmacology; Risperidone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOPAMINE 2 RECEPTOR; DULOXETINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM SALT; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERGOLIDE; PLACEBO; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN 2A RECEPTOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL;

AKATHISIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DIABETES MELLITUS; DROWSINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSKINESIA; DYSMENORRHEA; DYSPEPSIA; DYSURIA; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERKINESIA; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; INCIDENCE; INSOMNIA; LACTATION DISORDER; LIBIDO DISORDER; MASTALGIA; MONOTHERAPY; MOOD; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PRACTICE GUIDELINE; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SOMNOLENCE; WEIGHT GAIN;

EID: 33745893765     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.2.127     Document Type: Review

References (44)

1. [ADA] American Diabetes Association; America Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27:596-601.
2. [APA] American Psychiatric Association. 2002. Practice guideline for the treatment of patients with bipolar disorder (revision). Washington, DC: APA.
3. Bahk WM, Yoon JS, Kim YH, et al. 2004. Risperidone in combination with mood stabilizers for acute mania: a multicenter, open study. Int Clin Psychopharmacol, 19:299-3003.
4. Biederman J. 2003. Open-label study of risperidone in children with bipolar disorder. Presented at the 16th annual meeting of the European Neuropsychopharmacology Congress [abstract]. 2003 September 20-24; Prague, Czech Republic. P.2.079.
5. Bowden CL, Myers JE, Grossman F, et al. 2004. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J Clin Psychiatry, 65:707-14.
6. Calabrese JR, Keck PE, Macfadden W, et al. 2005. A randomized,double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry, 162:1351-60.
7. [FDA] Food and Drug Administration Center for Drug Evaluation and Research. 2005. Public Health Advisory. April 11.
8. Fenton C, Scott LJ. 2005. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs, 19:429-44.
9. Frazier JA, Meyer MC, Biederman J, et al. 1999. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry, 38:960-5.
10. Fuller MA, Sajatovic M. 2005. Drug information handbook for psychiatry. Cleveland, OH: Lexi-Comp.
11. Ghaemi SN, Hsu DJ, Rosenquist KJ, et al. 2004. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry, 16:69-73.
12. Gopal S, Steffers DC, Kramer ML, et al. 2005. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry, 66:1016-20.
13. Guille C, Sachs GS, Ghaemi SN. 2000. A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry, 61:638-42.
14. Hirschfeld RM, Keck PE, Kramer M, et al. 2004. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double blind, placebo-controlled trial. Am J Psychiatry, 161:1057-65.
15. Hirschfeld RM, Calabrese JR, Weissman MM, et al. 2003. Screening for bipolar disorder in the community. J Clin Psychiatry, 64:53-9.
16. Janssen Pharmaceuticals 2003a. Risperdal® (Consta®) product information 2003. Titusville, NJ, USA: Janssen.
17. Janssen Pharmaceuticals 2003b. Risperidone (Risperdal®) product information. Titusville, NJ, USA: Janssen.
18. Kalkman HO, Loetscher E, 2003. alpha-adrenoreceptor blockade by clozapine and other antipsychotic drugs. Eur J Pharmacol, 462: 33-40.
19. Keck PE, Perlis RH, Otto MW, et al. 2004. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgrad Med Special Report:1-120.
20. Khanna S, Vieta E, Lyons B, et al. 2003. Risperidone monotherapy in acute bipolar mania [poster]. Fifth International conference on bipolar disorder (ICBD). 2003; Pittsburgh, USA.
21. Khanna S, Vieta E, Lyons B, et al. 2005. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry, 187:229-34.
22. Kogan JN, Otto MW, Bauer M, et al. 2004. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the systematic treatment enhancement program for bipolar disorder (STEP BD). Bipolar Disord, 6:460-9.
23. Kowatch RA, Fristad M, Bermaher B, et al. 2005. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 44:213-35.
24. Leyson JE, Janssen PM, Megens AA, et al. 1994. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry, 55(Suppl):5-12.
25. Licht RW, Bysted M, Christensen H, 2001. Fixed-dose risperidone in mania: an open experimental trial. Int Clin Psychopharmacol, 16: 103-10.
26. Lindenmayer JP, Czobor P, Volavka J et al. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatiy, 160:290-6.
27. McIntyre RS, Mancini DA, Srinivasan J, et al. 2004. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can J Clin Pharmacol, 11:218-26.
28. Newcomer JW, Haupt DW, Fucetola R, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry, 59:337-45.
29. Pania L, Gessab GL, 2002. Dopaminergic deficit and mood disorders. Int Clin Psychopharmacol, 17(Suppl 4):S1-7.
30. Petrie W, 2004. Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who are receiving a primary thymoleptic agent. American Psychiatric Association 157th Annual Meeting. 2004 May 1-6; New York, USA.
31. Regier DA, Narrow WE, Rae DS, et al. 1993. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatr, 50:85-94.
32. Sachs GS, Grossman F, Ghaemi SN, et al. 2002. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry, 159:1146-54.
33. Sachs GS. 2004. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatr Scand, 422(Suppl):7-17
34. Sajatovic M, Blow FC, Ignacio RV, et al. 2004. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv, 55:1014-21.
35. Sajatovic M, Madhusoodanan S, Fuller MA, et al. 2005. Risperidone for bipolar disorders. Expert Rev Neurother, 5:177-87.
36. Sajatovic M, Ramirez L, Vernon L, et al. 1996. Outcomes of risperidone therapy for elderly patients with chronic psychosis. Int J Psychiatry Med, 26:309-17.
37. Segal J, Berk M, Brook S, 1998. Risperidone compared with both lithium and haloperidol in mania: A double-blind, randomized controlled trial. Clin Neuropharmacol, 21:176-80.
38. Shelton RC, Stahl SM, 2004. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry, 65: 1715-19.
39. Smulevich AB, Khanna S, Eedekens M, 2005. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol, 15:75-84.
40. Stahl SM, Shelton RC, 2001. Risperidone with and without paroxetine compared with paroxetine alone for bipolar depression. 41st Annual meeting of the American College of Neuropsychopharmacology (ACNP). 2001; Hawaii, USA.
41. Vieta E, Bruge E, Goikolea JM, et al. 2004. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol, 19:41-5.
42. Vieta E, Goikolea JM, Corbella B, et al. 2001. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry, 62:818-25.
43. Vieta E, Herraiz M, Parramon G, et al. 2002. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord, 72:15-19.
44. Yatham LN, Grossman F, Augustyns I, et al. 2003. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J Psychiatry, 182: 141-7.